top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago


Gene Therapy for Huntington's Disease: Everything We've Covered
uniQure's AMT-130 is the first Huntington's gene therapy to reach the FDA with long-term data behind it. Every Gene Tech Times story on it, in order, with what to watch before the May 2027 decision.
17 hours ago


enGene's Non-Viral Gene Therapy for Bladder Cancer Heads to the FDA
enGene's non-viral gene therapy detalimogene cleared detectable cancer in 56% of evaluated patients with BCG-unresponsive bladder cancer, and 86% kept their bladders. The company plans to start its FDA application by the end of 2026.
6 days ago


FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies: What Changes
FDA's final potency assurance guidance replaces its 2011 potency test guidance and asks cell and gene therapy makers to build a risk-based strategy so every lot works as intended.
Nov 7


FDA Approves Voceryq, the First Plasmid DNA Immunotherapy, for Recurrent Respiratory Papillomatosis
The FDA approved Inovio's Voceryq, its first plasmid DNA immunotherapy, for adults with recurrent respiratory papillomatosis. Here's how it works and what the trial showed.
Nov 1


FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
A new FDA draft guidance would let one license cover a personalized gene editor and its patient-specific versions. New mutations could be added with lab data instead of new clinical trials, a path built for cases like KJ Muldoon's.
Oct 29


Estuary Launches With $103 Million to Bring Gene Therapy to Polycystic Kidney Disease
Estuary Biotherapeutics launched with $103 million to develop one-time, kidney-directed AAV gene therapies for ADPKD, the most common inherited kidney disease. Here is how restoring polycystin proteins could stop, or even reverse, kidney cysts.
Oct 22


Should Gene Therapy Be Used for Common Diseases? Two Cardiologists Propose Five Questions
One-time genetic treatments are moving from rare diseases to common ones like high cholesterol. In JAMA Internal Medicine, two University of Michigan cardiologists explain why permanence, rare side effects and cost call for a new framework.
Oct 22


The 2026 Nobel Prize for Optogenetics Is Also a Gene Therapy Story
The 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, Peter Hegemann and Georg Nagel for light-gated ion channels and optogenetics. Here's how an algae gene became a tool for neuroscience, and why the first optogenetic gene therapy for blindness is now under FDA review.
Oct 10


No, CRISPR Hasn't Cured Down Syndrome. Here's What the Viral Study Really Showed
A viral post claims scientists can now remove the extra chromosome behind Down syndrome. The 2025 Mie University study is real, but it was done in lab-grown cells, not babies, and it is far from a treatment. Here is the myth vs. fact.
Oct 5


One CRISPR Infusion Kept Cholesterol and Triglycerides Down for a Full Year
One-year data for CTX310, a single-infusion CRISPR therapy that switches off ANGPTL3 in the liver, showed LDL cholesterol down 53% and triglycerides down 48% at the top dose, with no treatment-related serious side effects.
Oct 5


Beacon's Gene Therapy for X-Linked Retinitis Pigmentosa Succeeds in a Pivotal Trial
Laru-zova met its primary goal in the pivotal VISTA trial: 31% of high-dose patients gained three or more lines of dim-light vision, versus none in the control group. It is the first XLRP gene therapy to win a late-stage trial.
Oct 4


Four Years In, uniQure's Huntington's Gene Therapy Still Slows Decline as It Heads to the FDA
Four-year data for AMT-130 show high-dose patients losing everyday function 61% more slowly than matched untreated patients, but a key composite score weakened. Here's what the results mean as the FDA reviews uniQure's application.
Oct 3


FDA Grants Priority Review to What Could Be the World's First In Vivo CRISPR Therapy
The FDA accepted Intellia's application for lonvo-z in hereditary angioedema with priority review, setting a March 10, 2027 decision date. It could be the first CRISPR therapy that edits genes inside the body.
Sep 7


One CRISPR Dose, 87% Fewer Attacks: Inside Intellia's Phase 3 Win for Hereditary Angioedema
Intellia's one-time CRISPR therapy lonvo-z cut hereditary angioedema attacks by 87% in the Phase 3 HAELO trial. In its August update, the company set a U.S. launch target of early 2027. Here's how it works.
Aug 5


Casgevy, the First CRISPR Medicine, Expands to Children as Young as 2
The FDA expanded Vertex's CRISPR therapy Casgevy to children aged 2 and older with sickle cell disease or transfusion-dependent beta-thalassemia. Here's how it works and why the approval for toddlers is notable.
Jul 29


Prime Medicine Wins Arbitration Against Beam, Clearing the Way for Its AATD Prime Editor
An arbitration tribunal confirmed Prime Medicine's rights to PM647, a prime-editing therapy for alpha-1 antitrypsin deficiency, ending a dispute with Beam Therapeutics. Here's the science and what comes next.
Jul 7


FDA Reverses Course on uniQure's Huntington's Gene Therapy
In June 2026 the FDA agreed that three-year data for uniQure's AMT-130 could support accelerated approval for Huntington's disease, reversing its late-2025 stance. Here's the science and the regulatory drama.
Jun 16


FDA Draft Guidance Lets Gene-Editing Developers Build on What's Already Known
A June 2026 FDA draft guidance lets developers of genome-editing therapies reuse prior manufacturing, nonclinical and clinical knowledge. Here's why the platform approach could speed rare-disease cures.
Jun 2


One Infusion, Lower Cholesterol: Early Data Back Lilly's Bet on Verve
Phase 1 data for VERVE-102, a one-time base-editing treatment that switches off PCSK9, showed LDL cholesterol cuts of up to 62% lasting up to 18 months. Here's what it means for heart disease.
May 24
bottom of page


